Wednesday, March 12, 2025 7:41:28 AM
Who are they? Herman H. Yue
Partner
He/Him/His
New York
herman.yue@lw.com
+1.212.906.2977
Download
Download
Share this pages
Profile
Experience
Qualifications
News & Insights
Yue, Herman H.
Herman H. Yue
Partner
herman.yue@lw.com
Profile
Experience
Qualifications
News & Insights
Profile
Dr. Herman Yue devises sophisticated intellectual property solutions for clients, particularly within the life sciences and biopharmaceutical space.
Herman leverages his molecular biology expertise and broad-ranging experience across all phases of patent litigation to help clients — ranging from cutting-edge startups to Fortune 50 industry leaders — advance highly technical legal solutions that address:
Patent infringement actions
Litigation under the Biologics Price Competition and Innovation Act (BPCIA) and Hatch-Waxman Act
Inter partes review proceedings before the US Patent and Trademark Office (USPTO)
Cross-border proceedings involving patent offices and courts in various jurisdictions around the world, including Europe, Japan, China, and South Korea
He engages quickly with clients on both the technical and legal issues that arise in IP matters across a broad range of technologies, including biologics, small molecule pharmaceuticals, gene editing, computer technology, and medical devices. Herman routinely provides analysis in anticipation of litigation and IP due diligence in the context of larger transactions.
Herman maintains an active pro bono practice, including immigration asylum cases and predatory housing matters.
Before practicing law, Herman earned a doctorate in immunology and holds a US patent based on his graduate research on the mammalian TRAIL receptor.
He served as a law clerk to the late Judge Robert W. Sweet of the Southern District of New York.
Partner
He/Him/His
New York
herman.yue@lw.com
+1.212.906.2977
Download
Download
Share this pages
Profile
Experience
Qualifications
News & Insights
Yue, Herman H.
Herman H. Yue
Partner
herman.yue@lw.com
Profile
Experience
Qualifications
News & Insights
Profile
Dr. Herman Yue devises sophisticated intellectual property solutions for clients, particularly within the life sciences and biopharmaceutical space.
Herman leverages his molecular biology expertise and broad-ranging experience across all phases of patent litigation to help clients — ranging from cutting-edge startups to Fortune 50 industry leaders — advance highly technical legal solutions that address:
Patent infringement actions
Litigation under the Biologics Price Competition and Innovation Act (BPCIA) and Hatch-Waxman Act
Inter partes review proceedings before the US Patent and Trademark Office (USPTO)
Cross-border proceedings involving patent offices and courts in various jurisdictions around the world, including Europe, Japan, China, and South Korea
He engages quickly with clients on both the technical and legal issues that arise in IP matters across a broad range of technologies, including biologics, small molecule pharmaceuticals, gene editing, computer technology, and medical devices. Herman routinely provides analysis in anticipation of litigation and IP due diligence in the context of larger transactions.
Herman maintains an active pro bono practice, including immigration asylum cases and predatory housing matters.
Before practicing law, Herman earned a doctorate in immunology and holds a US patent based on his graduate research on the mammalian TRAIL receptor.
He served as a law clerk to the late Judge Robert W. Sweet of the Southern District of New York.
-----------------------------------------------------------------------------------------------
I believe in Elite, and its CEO Nasrat Hakim - This is why I am long !!!
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 12:05:23 PM
- Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets • Newsfile • 04/02/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 10:10:32 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information • Newsfile • 02/17/2026 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:06:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 09:35:26 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2026 Financial Results on February 18, 2026 • Newsfile • 02/11/2026 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2026 09:35:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 10:10:23 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information • Newsfile • 11/14/2025 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:11:38 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/12/2025 10:19:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 12:15:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/10/2025 12:15:46 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025 • Newsfile • 11/10/2025 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/26/2025 09:17:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/22/2025 01:39:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2025 08:37:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2025 08:35:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/25/2025 10:05:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/10/2025 08:17:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/08/2025 08:15:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/08/2025 02:58:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/30/2025 08:27:51 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 06/30/2025 08:05:59 PM
